These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

842 related items for PubMed ID: 8290970

  • 1. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F, Fernández-Barbieri MA, Santarelli MT, Matus-Ridley M, Rosso A, Negri-Aranguren P, Cerutti I, Gomel M, Kvicala R.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [Abstract] [Full Text] [Related]

  • 2. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Dec; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 3. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R, Ho AD, Del Valle F, Fischer JT, Ehrhardt R, Döhner H, Witt B, Huberts H, Kaplan E, Hunstein W.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [Abstract] [Full Text] [Related]

  • 4. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 5. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ, Gallant G, Williams GJ, Woloschuk D, Shore TB, Rubinger M, Schacter BA.
    Cancer; 1998 Oct 01; 83(7):1344-54. PubMed ID: 9762935
    [Abstract] [Full Text] [Related]

  • 6. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R, Lerede T, Buelli M, Borleri G, Bellavita P, Rambaldi A, Barbui T.
    Haematologica; 1998 May 01; 83(5):422-7. PubMed ID: 9658726
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
    Lange BJ, Dinndorf P, Smith FO, Arndt C, Barnard D, Feig S, Feusner J, Seibel N, Weiman M, Aplenc R, Gerbing R, Alonzo TA.
    J Clin Oncol; 2004 Jan 01; 22(1):150-6. PubMed ID: 14701777
    [Abstract] [Full Text] [Related]

  • 9. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M.
    Br J Haematol; 2005 Oct 01; 131(2):172-9. PubMed ID: 16197446
    [Abstract] [Full Text] [Related]

  • 10. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U, Berthold F, Boos J, Fleischhack G, Gadner H, Gnekow A, Graubner U, Henze G, Hermann J, Imbach P, Jürgens H, Kabisch H, Körholz D, Niemeyer CM, Reinhardt D, Reiter A, Ritter J, Spaar HJ, Zimmermann M, AML-BFM-Studien-Gruppe.
    Klin Padiatr; 2001 Oct 01; 213(4):175-85. PubMed ID: 11528551
    [Abstract] [Full Text] [Related]

  • 11. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
    Ruutu T, Almqvist A, Hallman H, Honkanen T, Järvenpää E, Järventie G, Koistinen P, Koivunen E, Lahtinen R, Lehtinen M.
    Leukemia; 1994 Jan 01; 8(1):11-5. PubMed ID: 8289475
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
    Mehta J, Powles R, Singhal S, Horton C, Hamblin M, Zomas A, Saso R, Prendiville J, Glynne P, Allford S, Mackay H, Treleaven J.
    Semin Hematol; 1996 Oct 01; 33(4 Suppl 3):18-23. PubMed ID: 8916312
    [Abstract] [Full Text] [Related]

  • 14. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
    Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA.
    Cancer Chemother Pharmacol; 2004 Jun 01; 53(6):468-74. PubMed ID: 15138711
    [Abstract] [Full Text] [Related]

  • 15. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M, Tokyo Children's Cancer Study Group.
    Pediatr Blood Cancer; 2007 Aug 01; 49(2):127-32. PubMed ID: 16807916
    [Abstract] [Full Text] [Related]

  • 16. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia.
    Saşmaz I, Tanyeli A, Bayram I, Antmen B, Yilmaz L, Küçükosmanoğlu O, Kilinç Y.
    Turk J Pediatr; 2004 Aug 01; 46(1):32-7. PubMed ID: 15074372
    [Abstract] [Full Text] [Related]

  • 17. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug 01; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 18. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Visani G, Lemoli RM, Isidori A, Piccaluga PP, Martinelli G, Malagola M, Gugliotta L, Bonini A, Bonifazi F, Motta MR, Rizzi S, Castellani S, Tura S.
    Bone Marrow Transplant; 2001 Apr 01; 27(8):829-35. PubMed ID: 11477440
    [Abstract] [Full Text] [Related]

  • 19. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS, Kim DW, Kim CC, Kim HK, Kim JS, Hwang TJ, Kim HJ, Kim HS, Song HS, Park JW, Ahn HS, Chung TJ, Cho KS, Lee KS, Choi YM.
    Semin Hematol; 1996 Oct 01; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [Abstract] [Full Text] [Related]

  • 20. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA, Children's Cancer Group Study 2951.
    J Clin Oncol; 2003 Aug 01; 21(15):2940-7. PubMed ID: 12885813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.